Alternative Solid Forms: Co-crystals

Johan Wouters, Dario Braga, Fabrizia Grepioni, Luc Aerts, Luc Quéré

Research output: Contribution in Book/Catalog/Report/Conference proceedingChapter

Abstract

The relevance of co‐crystals for pharmaceutical development is demonstrated by the constant growth of the number of papers and patents published in the two last decades. Co‐crystallization appears to be an efficient means to modulate the solid state properties of a pharmaceutical active ingredient (API) within the crystalline state. It is also a crystal engineering approach enabling to prepare original materials, including co‐drugs. Co‐crystallization is therefore a route to innovation and opens perspectives to patent protection. Alternatively, co‐crystal formation may represent an undesired or unexpected outcome of molecular complexation, for example in the drug product. This observation underlines the importance of a detailed study on the solid state chemistry not only of the pure API, but also of its combinations with the individual components in the formulation.
Original languageEnglish
Title of host publicationPolymorphism in the Pharmaceutical Industry : Solid Forms and Drug Development
EditorsRolf Hilfiker, Markus von Raumer
PublisherWiley
Chapter3
Number of pages32
DOIs
Publication statusPublished - 2018

Fingerprint

Crystals
Crystal engineering
Pharmaceutical Preparations
Complexation
Drug products
Innovation
Crystalline materials

Cite this

Wouters, J., Braga, D., Grepioni, F., Aerts, L., & Quéré, L. (2018). Alternative Solid Forms: Co-crystals. In R. Hilfiker, & M. von Raumer (Eds.), Polymorphism in the Pharmaceutical Industry : Solid Forms and Drug Development Wiley. https://doi.org/10.1002/9783527697847.ch3
Wouters, Johan ; Braga, Dario ; Grepioni, Fabrizia ; Aerts, Luc ; Quéré, Luc . / Alternative Solid Forms : Co-crystals. Polymorphism in the Pharmaceutical Industry : Solid Forms and Drug Development. editor / Rolf Hilfiker ; Markus von Raumer. Wiley, 2018.
@inbook{ee11486e737b44cb8b177e124b76f41f,
title = "Alternative Solid Forms: Co-crystals",
abstract = "The relevance of co‐crystals for pharmaceutical development is demonstrated by the constant growth of the number of papers and patents published in the two last decades. Co‐crystallization appears to be an efficient means to modulate the solid state properties of a pharmaceutical active ingredient (API) within the crystalline state. It is also a crystal engineering approach enabling to prepare original materials, including co‐drugs. Co‐crystallization is therefore a route to innovation and opens perspectives to patent protection. Alternatively, co‐crystal formation may represent an undesired or unexpected outcome of molecular complexation, for example in the drug product. This observation underlines the importance of a detailed study on the solid state chemistry not only of the pure API, but also of its combinations with the individual components in the formulation.",
author = "Johan Wouters and Dario Braga and Fabrizia Grepioni and Luc Aerts and Luc Qu{\'e}r{\'e}",
year = "2018",
doi = "http://dx.doi.org/10.1002/9783527697847.ch3",
language = "English",
editor = "Rolf Hilfiker and {von Raumer}, Markus",
booktitle = "Polymorphism in the Pharmaceutical Industry : Solid Forms and Drug Development",
publisher = "Wiley",

}

Wouters, J, Braga, D, Grepioni, F, Aerts, L & Quéré, L 2018, Alternative Solid Forms: Co-crystals. in R Hilfiker & M von Raumer (eds), Polymorphism in the Pharmaceutical Industry : Solid Forms and Drug Development. Wiley. https://doi.org/10.1002/9783527697847.ch3

Alternative Solid Forms : Co-crystals. / Wouters, Johan; Braga, Dario; Grepioni, Fabrizia; Aerts, Luc; Quéré, Luc .

Polymorphism in the Pharmaceutical Industry : Solid Forms and Drug Development. ed. / Rolf Hilfiker; Markus von Raumer. Wiley, 2018.

Research output: Contribution in Book/Catalog/Report/Conference proceedingChapter

TY - CHAP

T1 - Alternative Solid Forms

T2 - Co-crystals

AU - Wouters, Johan

AU - Braga, Dario

AU - Grepioni, Fabrizia

AU - Aerts, Luc

AU - Quéré, Luc

PY - 2018

Y1 - 2018

N2 - The relevance of co‐crystals for pharmaceutical development is demonstrated by the constant growth of the number of papers and patents published in the two last decades. Co‐crystallization appears to be an efficient means to modulate the solid state properties of a pharmaceutical active ingredient (API) within the crystalline state. It is also a crystal engineering approach enabling to prepare original materials, including co‐drugs. Co‐crystallization is therefore a route to innovation and opens perspectives to patent protection. Alternatively, co‐crystal formation may represent an undesired or unexpected outcome of molecular complexation, for example in the drug product. This observation underlines the importance of a detailed study on the solid state chemistry not only of the pure API, but also of its combinations with the individual components in the formulation.

AB - The relevance of co‐crystals for pharmaceutical development is demonstrated by the constant growth of the number of papers and patents published in the two last decades. Co‐crystallization appears to be an efficient means to modulate the solid state properties of a pharmaceutical active ingredient (API) within the crystalline state. It is also a crystal engineering approach enabling to prepare original materials, including co‐drugs. Co‐crystallization is therefore a route to innovation and opens perspectives to patent protection. Alternatively, co‐crystal formation may represent an undesired or unexpected outcome of molecular complexation, for example in the drug product. This observation underlines the importance of a detailed study on the solid state chemistry not only of the pure API, but also of its combinations with the individual components in the formulation.

U2 - http://dx.doi.org/10.1002/9783527697847.ch3

DO - http://dx.doi.org/10.1002/9783527697847.ch3

M3 - Chapter

BT - Polymorphism in the Pharmaceutical Industry : Solid Forms and Drug Development

A2 - Hilfiker, Rolf

A2 - von Raumer, Markus

PB - Wiley

ER -

Wouters J, Braga D, Grepioni F, Aerts L, Quéré L. Alternative Solid Forms: Co-crystals. In Hilfiker R, von Raumer M, editors, Polymorphism in the Pharmaceutical Industry : Solid Forms and Drug Development. Wiley. 2018 https://doi.org/10.1002/9783527697847.ch3